Health Economics›Follicular lymphoma›Early disease definitive therapy

Early disease definitive therapy

Follicular lymphoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibritumomab tiuxetan protocol Variant #18 Partial	—	—	8d	~36.5 mo	—	~1	—	1
Radiation therapy N/A - radiation	—	—	49d	~25.5 mo	~10.6 mo	—	—	24

2 of 2 regimens shown